Overview

Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
0
Participant gender:
All
Summary
Administration of eplerenone within 24 hours of onset of symptoms of myocardial infarction, in patients without heart failure, reduces cardiovascular mortality / morbidity.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Eplerenone
Spironolactone
Criteria
Inclusion Criteria:

- Subjects must have experienced a myocardial infarction (STEMI) within the previous 24
hours confirmed by symptoms and ECG.

Exclusion Criteria:

- Subjects with a known low ejection fraction of less than 40% or any previous history
of heart failure.

- Subjects treated with eplerenone or other aldosterone antagonists within the past 1
month.

- The subject has uncontrolled hypotension (SBP<90mmHg).

- Subjects with eGFR ≤30ml/min (based on admission serum creatinine and the MDRD
formula) or serum creatinine ≥220µmol/L.